- Home
- TECX vs CADL Comparison
TECX vs CADL Comparison
Compare TECX & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- CADL
- Stock Information
- Founded
- TECX 2019
- CADL 1999
- Country
- TECX United States
- CADL United States
- Employees
- TECX N/A
- CADL N/A
- Industry
- TECX
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- TECX
- CADL Health Care
- Exchange
- TECX Nasdaq
- CADL Nasdaq
- Market Cap
- TECX 387.1M
- CADL 339.8M
- IPO Year
- TECX 2018
- CADL 2021
- Fundamental
- Price
- TECX $18.92
- CADL $4.90
- Analyst Decision
- TECX Buy
- CADL Strong Buy
- Analyst Count
- TECX 6
- CADL 7
- Target Price
- TECX $79.17
- CADL $19.57
- AVG Volume (30 Days)
- TECX 682.4K
- CADL 630.6K
- Earning Date
- TECX 11-06-2025
- CADL 11-14-2025
- Dividend Yield
- TECX N/A
- CADL N/A
- EPS Growth
- TECX N/A
- CADL N/A
- EPS
- TECX N/A
- CADL N/A
- Revenue
- TECX N/A
- CADL N/A
- Revenue This Year
- TECX N/A
- CADL N/A
- Revenue Next Year
- TECX N/A
- CADL N/A
- P/E Ratio
- TECX N/A
- CADL N/A
- Revenue Growth
- TECX N/A
- CADL N/A
- 52 Week Low
- TECX $13.70
- CADL $3.79
- 52 Week High
- TECX $61.07
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- TECX 55.49
- CADL 39.05
- Support Level
- TECX $18.49
- CADL $4.77
- Resistance Level
- TECX $20.39
- CADL $5.32
- Average True Range (ATR)
- TECX 2.22
- CADL 0.26
- MACD
- TECX 0.14
- CADL -0.05
- Stochastic Oscillator
- TECX 31.09
- CADL 12.72
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.